Targeting of cancer cells with monoclonal antibodies specific for C3b(i).
OBJECTIVE
The goal of this research is to determine the feasibility of an immunotherapeutic approach based on the use of monoclonal antibodies (mAb) to target complement activation fragments on opsonized cancer cells.


METHODS
We investigated whether treatment of LNCaP and C4-2 human prostate cancer cell lines with normal human serum would allow for deposition of sufficient amounts of the complement-activation protein C3b and its fragments [collectively referred to as C3b(i)] such that these proteins could serve as cancer-cell-associated antigens for targeting by mAb. Radioimmunoassays, flow cytometry, and magnetic purging with specific immunomagnetic beads were used for the analyses.


RESULTS
In vitro opsonization of human prostate cancer cells with normal human serum resulted in deposition of C3b(i) in sufficient quantity (approx. 100,000 molecules/cell) for the cells to be targeted in a variety of protocols. We found that 51Cr-labeled and C3b(i)-opsonized cancer cells could be specifically purged at high efficiency (95%-99%) using anti-C3b(i) mAb covalently coupled to magnetic beads. Flow-cytometry experiments indicated that most normal white cells were not removed under similar conditions. Opsonization of cancer cells with sera from men with prostate cancer led to lower levels of cell-associated IgM and, subsequently, lower amounts of C3b(i) deposited than in normal subjects. Prototype experiments suggested that this deficiency could be corrected by addition of IgM from normal donor plasma.


CONCLUSIONS
mAb directed against complement-activation products may provide new opportunities to deliver diagnostic and therapeutic agents selectively to cancer cells and tumor deposits. These opportunities may include ex vivo purging of C3b(i)-opsonized cancer cells prior to autologous bone marrow or stem cell transplantation.
Sokoloff
M H
MH
Department of Urology, University of Virginia School of Medicine, Charlottesville, USA.
Nardin
A
A
Solga
M D
MD
Lindorfer
M A
MA
Sutherland
W M
WM
Bankovich
A J
AJ
Zhau
H E
HE
Chung
L W
LW
Taylor
R P
RP
D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology / Q000473:pathology*; D000728:Androgens; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D016465:Bone Marrow Purging; D003179:Complement C3b / Q000276:immunology*; D005240:Feasibility Studies; D005434:Flow Cytometry; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D007159:Immunologic Tests; D018189:Immunomagnetic Separation; D007167:Immunotherapy; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000276:immunology / Q000473:pathology; D009895:Opsonin Proteins / Q000097:blood / Q000276:immunology; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology*; D012397:Rosette Formation; D014407:Tumor Cells, Cultured / Q000276:immunology
D000728:Androgens; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D007075:Immunoglobulin M; D009895:Opsonin Proteins; D003179:Complement C3b